Patents by Inventor Marc Gitzinger
Marc Gitzinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11903934Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: GrantFiled: May 27, 2022Date of Patent: February 20, 2024Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
-
Publication number: 20240041845Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: ApplicationFiled: October 20, 2023Publication date: February 8, 2024Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20240000759Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: ApplicationFiled: September 12, 2023Publication date: January 4, 2024Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Patent number: 11833139Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: GrantFiled: June 6, 2022Date of Patent: December 5, 2023Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20230364065Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a member of the polymyxin class of antibiotics, such as commercially available natural products antibiotics, e.g., polymyxins B and polymyxins E (colistin and its pro-drug colistin methane sulfonate (CMS)) and synthetic or semi-synthetic derivatives and analogs, e.g., SPR206, MRX-8 and QPX9003 and polymyxin-like antibiotics, e.g.Type: ApplicationFiled: November 1, 2022Publication date: November 16, 2023Inventors: Sergio Lociuro, Glenn E. Dale, Marc Gitzinger, Vincent Trebosc
-
Patent number: 11766425Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: GrantFiled: December 27, 2021Date of Patent: September 26, 2023Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Publication number: 20230132691Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: ApplicationFiled: June 6, 2022Publication date: May 4, 2023Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20230066182Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: ApplicationFiled: May 27, 2022Publication date: March 2, 2023Inventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
-
Publication number: 20220184048Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: ApplicationFiled: December 27, 2021Publication date: June 16, 2022Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Patent number: 11351158Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: GrantFiled: August 3, 2020Date of Patent: June 7, 2022Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Patent number: 11344537Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: GrantFiled: August 3, 2020Date of Patent: May 31, 2022Assignee: BIOVERSYS AGInventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
-
Publication number: 20220024928Abstract: The present invention relates to a compound according to formula (I), wherein R1 and R5 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, —Cn-alkyl-N(R12)(R13) with n=0-3, —Cn-alkyl-C(O)N(R12)(R13) with n=0-3, —SO2—N(R14)-C(O)—R15; —Cn-alkyl-N(R14)-C(O)—R15 with n=0-3, —Cn-alkyl-C(O)—OR16 with n=0-3, —O(C1-C3-alkyl-O)m—C1-C3-alkyl-OR10 with m=0-3, —Cn-alkyl-OR16 with n=0-3, —NH—Cn-alkyl-R18 with n=0-3; —O—Cn-alkyl-R18 with n=0-3; —OPO(OR10)2, —PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R3 is selected from halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, —Cn-alkyl-N(R12)(R13) with n=0-3, —Cn-alkyl-C(O)N(R12)(R13) with n=0-3, —SO2—N(R14)-C(O)—R15; —Cn-alkType: ApplicationFiled: November 27, 2019Publication date: January 27, 2022Inventors: Marilyne BOUROTTE, Michel PIEREN, Sergio LOCIURO, Marc GITZINGER, Christian KEMMER, Birgit SCHELLHORN, Julian SCHILL, Peter SCHNEIDER
-
Patent number: 11207305Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: GrantFiled: August 3, 2020Date of Patent: December 28, 2021Assignee: BIOVERSYS AGInventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Publication number: 20210222181Abstract: The present invention relates to the field of bacterial vectors and methods for genetic manipulation of bacteria. In particular, the present invention relates to a vector for genetic manipulation of a bacterium, wherein said vector comprises (a) a non-antibiotic selection marker gene cassette, (b) an origin of replication, wherein said origin of replication is not capable of inducing replication of said vector in said bacterium, and (c) a restriction endonuclease gene, a recognition site of a restriction endonuclease encoded by said restriction endonuclease gene, and a second regulatory sequence. Further, the invention relates to a bacterial host cell comprising said vector, a method for genetic manipulation of bacteria using the vector of the invention, and methods for selecting bacterial host cells.Type: ApplicationFiled: May 15, 2019Publication date: July 22, 2021Inventors: Christian KEMMER, Vincent TREBOSC, Michel PIEREN, Marc GITZINGER, Birgit SCHELLHORN
-
Publication number: 20210077471Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: ApplicationFiled: August 3, 2020Publication date: March 18, 2021Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20210077470Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: ApplicationFiled: August 3, 2020Publication date: March 18, 2021Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
-
Publication number: 20210077472Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: ApplicationFiled: August 3, 2020Publication date: March 18, 2021Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Patent number: 9682079Abstract: The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.Type: GrantFiled: February 3, 2014Date of Patent: June 20, 2017Assignee: BIOVERSYS AGInventors: Peter Schneider, Rainer Riedl, Marcel Tigges, Marc Gitzinger, Michel Pieren, Assaf Levi, Mark Sephton, Birgit Schellhorn, Patrik Zueger, Michael Brand, Daniel Gygax, Peter Spies
-
Publication number: 20150359791Abstract: The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.Type: ApplicationFiled: February 3, 2014Publication date: December 17, 2015Inventors: Peter Schneider, Rainer Riedl, Marcel Tigges, Marc Gitzinger, Michel Pieren, Assaf Levi, Mark Sephton, Birgit Schellhorn, Patrik Zueger, Michael Brand, Daniel Gygax, Peter Spies
-
Patent number: 8912329Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; R2 is (CH2)n wherein n is 0, 1, 2, 3 or 4; R3 is (CH2)mR3A wherein m is 0, 1, 2, 3 or 4, and R3A is methyl, isopropyl, tert-butyl, OCH3, OH, optionally substituted phenoxy, C?CH, C?N, optionally substituted phenyl, furanyl or thienyl; A is a ring containing X1 with the meaning O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; and a compound of formula (2) wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N?CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.Type: GrantFiled: June 25, 2010Date of Patent: December 16, 2014Assignee: Bioversys AGInventors: Ronald Schoenmakers, Wilfried Weber, Marc Gitzinger, Martin Fussenegger, Marcel Tigges, Peter Schneider